AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationBone Marrow CellsGraft vs Host DiseaseBone MarrowTransplantation ConditioningBone Marrow TransplantationTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTransplantation ChimeraStem CellsHematopoietic Stem CellsTreatment OutcomeGraft vs Leukemia EffectBusulfanTissue DonorsMyeloablative AgonistsRemission InductionRecurrenceVidarabineGraft vs Tumor EffectGraft SurvivalLeukemiaLeukemia, Myeloid, AcuteHistocompatibility TestingWhole-Body IrradiationLymphocyte TransfusionImmunosuppressive AgentsMultiple MyelomaBone and BonesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRetrospective StudiesMyelodysplastic SyndromesCombined Modality TherapyLymphocyte DepletionCytomegalovirus InfectionsCord Blood Stem Cell TransplantationSiblingsMinor Histocompatibility AntigensTime FactorsPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival AnalysisDisease-Free SurvivalSalvage TherapyHistocompatibilityAntilymphocyte SerumAdrenal Cortex HormonesNeoplasm, ResidualSurvival RateLiver TransplantationAntigens, CD34T-LymphocytesCell DifferentiationVirus ActivationCyclophosphamideAnemia, AplasticMelphalanHematopoiesisChimerismMesenchymal Stem Cell TransplantationHematopoietic Stem Cell MobilizationAcute DiseaseHepatic Veno-Occlusive DiseaseMice, Inbred C57BLAntineoplastic Combined Chemotherapy ProtocolsCells, CulturedPrimary MyelofibrosisCell TransplantationLeukemia, MyeloidFlow CytometryCytomegalovirusFollow-Up StudiesColony-Forming Units AssayHematologic DiseasesGranulocyte Colony-Stimulating FactorPrognosisHLA AntigensImmunosuppressionBone Marrow DiseasesTransplantation ImmunologyKidney TransplantationCytarabineEmbryonic Stem CellsLeukemia, Myeloid, Accelerated PhaseFusion Proteins, bcr-ablAntineoplastic AgentsRadiation ChimeraLymphoproliferative DisordersBenzamidesImmunocompromised HostAntibodies, NeoplasmGraft RejectionAntibodies, MonoclonalTransplantation, IsogeneicAdult Stem CellsRoseolovirus InfectionsHodgkin DiseaseLymphoma, Non-Hodgkin
HSCTGVHDAutologousHematopoietic stemSystemicEnlarged spleenChemotherapyOutcomesGraftDonorPatientsSevereIndication for transplantationHormone replacement medicinesPost-transplantationMycophenolate mofetilAbnormalAGVHDIntravenousMesenchymalHaematopoieticUmbilicalCurativeMalignantOrgansPlateletsCord bloodMalignancy-associatedProliferationRecipientsChronicLymphomaPatient'sAspirationAutoimmuneComplications1999LiverCancerBloodLymphoidSurvivalTreatmentClonalAbnormalitiesDonorsPeripheral T-cell and NK-cellClinicalImmuneBiopsyTherapyOccursMultiple myeloma
HSCT11
  • Hematopoietic stem cell transplantation (HSCT) results in the alteration of several components of the immune system. (medscape.com)
  • Patients who undergo HSCT experience a sequential suppression of host defenses, resulting in varying infectious risk at different phases of the transplantation process. (medscape.com)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers great opportunities for curing hematologic malignancies. (aai.org)
  • Since then, allogeneic hematopoietic stem cell transplantation (HSCT) has evolved to become a frequently used and effective therapy for many hematologic malignancies. (longdom.org)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
  • Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). (hindawi.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only curative modality for many hematological disorders. (hindawi.com)
  • In the section on aspergillosis, the revised recommendations include the use of a room with high-efficiency particulate air filters rather than laminar airflow as the protective environment for allogeneic HSCT recipients and the use of high-efficiency respiratory-protection devices (e.g. (cdc.gov)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • In this study, we also share our limited experiences with allogeneic HSCT in malignancy-associated HLH. (biomedcentral.com)
GVHD14
  • In GVHD, the donated stem cells view the recipient cells as foreign and attack recipient cells. (medscape.com)
  • Transplants from HLA-matched siblings are associated with a lower risk of GVHD and faster recovery of the recipient's immune system following transplantation. (medscape.com)
  • GVHD has been reported after syngeneic and autologous transplantation but is rare. (medscape.com)
  • Among 1462 patients who had allogeneic hematopoietic cell transplantation (HCT) between January 2000 and December 2005, 116 (7.9%) developed stage 3-4 gut GVHD. (nature.com)
  • The median time for onset of stage 3-4 gut GVHD was 35 (4-135) days after allogeneic HCT. (nature.com)
  • Eighty-five of the 116 patients (73%) had corticosteroid resistance before or within 2 weeks after the onset of stage 3-4 gut GVHD. (nature.com)
  • Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). (jemperli.com)
  • Graft-versus-host disease (GVHD) is one of the major obstacles for the success of allogeneic hematopoietic stem cell transplantation. (aai.org)
  • In this article, we report that the interaction between OX40L and OX40 is of critical importance for both induction and progression of acute GVHD (aGVHD) driven by human T cells. (aai.org)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • Cytotoxic T lymphocytes were determined as the cellular effectors of GVHD, and the key role of antigen-presenting cells (APCs) in T-lymphocyte activation was established during the following years [ 11 , 12 ]. (hindawi.com)
  • The ongoing REACH program also includes the phase III REACH2 trial (NCT02913261), comparing ruxolitinib versus best available therapy in patients with corticosteroid-refractory aGVHD after ASCT, as well as the phase III REACH3 trial (NCT03112603) examining ruxolitinib versus best available therapy in patients with corticosteroid-refractory chronic GVHD after bone marrow transplantation. (targetedonc.com)
  • Minor histocompatibility antigen differences likely account for GVHD in HLA-identical sibling stem cell transplants. (unboundmedicine.com)
Autologous6
Hematopoietic stem4
Systemic5
  • METHODS: This retrospective, case-control study included 14 patients with extensive cutaneous chronic graft-versus-host disease, resistant to systemic corticosteroid, treated with bath PUVA. (bvsalud.org)
  • The pathognomonic characteristic of HPS is the activation of well-differentiated macrophages, phagocyting erythrocytes, leukocytes and platelets in bone marrow, lymph nodes, spleen, liver and other organs, which can infiltrate almost anybody district and may account for many of its systemic features [ 3 ]. (biomedcentral.com)
  • Patients had received at most 1 systemic treatment beyond corticosteroids for aGVHD. (targetedonc.com)
  • Considering the boundaries of immunodeficiency and immune hypersensitivity in MAS related to systemic juvenile idiopathic arthritis and adult-onset Still disease, and the role of lymphoid cells, severe COVID-19 is generally a distinctive lung-specific immunopathology. (nature.com)
  • In an era of advanced nanomedicine, it should be possible to restrain or reprogram the immune system directly using genetic engineering (Chapters 19 and 23 ), or by using other means (e.g., temporary systemic white cell sequestration), to reduce or eliminate immunoresponsiveness during the period of nanomedical treatment. (nanomedicine.com)
Enlarged spleen1
  • As the disease progresses, patients may experience the following symptoms which are the result of an enlarged spleen, abnormal blood cell production, and the release of too many cytokines into the blood. (radiationoncologyassociates.co)
Chemotherapy1
  • The superior clinical outcomes of allogeneic SCT versus chemotherapy alone as post-remission treatment could be related to the graft-versus-leukemia (GVL) effects of recovered donor T cells. (biomedcentral.com)
Outcomes2
  • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. (harvard.edu)
  • This study compared the effects of pre-transplantation minimal residual disease (pre-MRD) on outcomes in AML patients who underwent human leukocyte antigen-matched sibling donor transplantation (MSDT) or who received unmanipulated haploidentical allografts. (biomedcentral.com)
Graft11
  • BACKGROUND: Chronic graft-versus-host disease is a severe complication of allogeneic stem cell and bone marrow transplantation. (bvsalud.org)
  • We analyzed the graft-versus-host disease clinical presentation and timing after allogeneic stem cell and bone marrow transplantation, bath PUVA doses, background diseases, additional treatments, and adverse effects. (bvsalud.org)
  • However, T-cell depletion is associated with higher rates of graft rejection and increased vulnerability to viral and fungal infections while the T-cell population is diminished. (medscape.com)
  • An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. (nature.com)
  • Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. (nature.com)
  • In addition, we are committed to graft engineering and vaccine development to enhance the ability of transplantation to control blood diseases. (harvard.edu)
  • A group from Germany and the United States reported that the EASIX is a reliable factor to predict the prognosis of acute graft-versus-host disease after allogeneic stem cell transplantation [ 9 ]. (biomedcentral.com)
  • The application is seeking the approval of the JAK1/JAK2 inhibitor as a treatment for patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids. (targetedonc.com)
  • Immediately after the graft has been implanted, it is necessary to prevent sensitization of pre-existing mature T cells capable of recognizing the graft. (nanomedicine.com)
  • Once the graft has escaped the initial acute phase rejection reactions, a cumulative unresponsiveness to the graft develops as the recipient is continually exposed to donor MHC, a stable state that sometimes depends on the development of antigen-specific T-suppressor cells [ 371 , 5349 - 5354 ]. (nanomedicine.com)
  • In due course, the stem cells in the bone marrow reconstitute the peripheral lymphoid system but the newly formed T cells seem to accept the graft as self [ 403 ]. (nanomedicine.com)
Donor6
  • When the donor is someone other than the recipient, the procedure is described as allogeneic transplantation. (medscape.com)
  • Allogeneic transplants are further categorized by the degree of human leukocyte antigen (HLA) match between the donor and recipient. (medscape.com)
  • I. Examine the anti-tumor activity and safety of administering patient-specific donor-derived (allogeneic) CD33-CAR T cells following lymphodepletion in research participants with CD33+ recurrent/refractory (r/r) acute myeloid leukemia ( AML ). (survivornet.com)
  • The Allogeneic bone-marrow transplantation represents the only curative treatment and requires a compatible donor HLA. (longdom.org)
  • We initially search a potential donor within the siblings of the patient by determining HLA type, true genetic identity card of the cells. (longdom.org)
  • Transplantation is the transfer of living cells, tissues, or organs from one person, the donor, to another, the recipient (e.g., a blood transfusion), or from one part of the body to another (e.g., skin grafts) with the goal of restoring a missing function [ 361 ]. (nanomedicine.com)
Patients22
  • The median CD4 count in patients infected with HIV who develop nocardiosis is approximately 35 cells/µL. (medscape.com)
  • Additional presentations at ESMO include subgroup analyses of Libtayo in advanced non-small cell lung cancer (NSCLC), focusing on such populations as squamous cell carcinoma and patients with varying levels of PD-L1 expression. (biospace.com)
  • Persistent nausea and anorexia after marrow transplantation: a prospective study of 78 patients. (nature.com)
  • The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients. (mayo.edu)
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
  • This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). (survivornet.com)
  • Patients undergo lymphodepletion therapy 3-5 days prior to CAR T cell infusion and receive anti-CD33 CAR T-cells intravenously (IV) on day 0. (survivornet.com)
  • Determine the safety and feasibility of administering T cells expressing an anti-BCMA CAR to patients with MM. (survivornet.com)
  • We explored whether stem cell therapy was effective for animal models and patients with Crohn's disease (CD). (biomedcentral.com)
  • CD patients maintained high remission rates for 3-24 months after transplantation. (biomedcentral.com)
  • In 15 to 20% of patients, plasma cells secrete only Bence Jones protein. (merckmanuals.com)
  • Several angiogenesis-related markers, including microvessel density, circulating endothelial cells, and tumor microenvironment, have been reported to be associated with the prognosis of patients with B-cell NHL [ 8 ]. (biomedcentral.com)
  • Patients and Methods To explore this possibility, we compared the effect on β- and α-cell function of transient intensive insulin therapy using lispro versus human regular insulin in a total of 21 type 2 diabetic patients who were randomly assigned to 14-days intensive insulin therapy consisting of bedtime NPH insulin plus three injections of mealtime lispro (n=11) or regular insulin (n=10). (go.jp)
  • The application was submitted based on findings from the pivotal phase II REACH1 trial, in which ruxolitinib combined with corticosteroids induced an overall response rate (ORR) of 55% at day 28 in patients with steroid-refractory aGVHD, meeting the primary endpoint of the study. (targetedonc.com)
  • The open-label, single-cohort, multicenter phase II REACH1 study accrued patients aged ≥12 years old who had received allogeneic hematopoietic stem cell transplantation and developed grade 2 to 4 steroid-refractory aGVHD. (targetedonc.com)
  • Overall, 80.3% of patients received peripheral blood stem cells, 18.3% received bone marrow, and 1.4% received cord blood as the stem cell source. (targetedonc.com)
  • Patients with CAEBV in the United States most often present with disease involving B or T cells, while in Asia, the disease usually involves T or NK cells. (frontiersin.org)
  • These patients are unable to control EBV infection and have infiltration of tissues by EBV positive T, NK, or less often B cells. (frontiersin.org)
  • Some patients with CAEBV have been reported to have impaired NK cell ( 8 ) or T cell activity ( 9 - 13 ) against EBV-infected cells. (frontiersin.org)
  • In addition, reduced numbers of EBV-specific T cells have been described in patients with CAEBV disease ( 10 ). (frontiersin.org)
  • Unlike healthy persons with infectious mononucleosis, patients with CAEBV disease often have low numbers of EBV-specific CD8 cells ( 10 ). (frontiersin.org)
  • A recent study showed that patients with CAEBV or infectious mononucleosis have a decrease in the TCR-beta repertoire and expanded T cell clones in their peripheral blood compared with healthy carriers of EBV ( 14 ). (frontiersin.org)
Severe3
  • In the present study, the case of a patient with diffuse large B-cell lymphoma evolving from grade 3a follicular lymphoma, who maintained a complete response for 4-years, and then presented with severe isolated thrombocytopenia, is reported. (spandidos-publications.com)
  • Investigations at admission revealed severe thrombocytopenia (PLT=3x10 9 /l), normal white blood cell count and hemoglobin, without any significant changes in hepatic and renal function tests, electrolyte levels, or coagulation. (spandidos-publications.com)
  • If moderate or severe (Grades 2 or 3) rash occurs, interrupt POTELIGEO and administer at least 2 weeks of topical corticosteroids. (nih.gov)
Indication for transplantation1
Hormone replacement medicines3
  • Your healthcare provider will check you for these problems during treatment with JEMPERLI and may treat you with corticosteroid or hormone replacement medicines. (jemperli.com)
  • Your healthcare provider may treat you with corticosteroids or hormone replacement medicines. (bavencio.com)
  • A member of your healthcare team will do blood tests to check for side effects during your treatment with OPDIVO and may treat you with a corticosteroid or hormone replacement medicines. (opdivo.com)
Post-transplantation1
  • If one of the brothers and sisters is compatible, we speak about geno-identical allogeneic transplantation having the advantage of reducing the complications post-transplantation. (longdom.org)
Mycophenolate mofetil1
  • Current posttransplant prophylaxis is primarily based on the use of nonspecific immunosuppressive drugs, which include corticosteroids, calcineurin inhibitors, methotrexate, mycophenolate mofetil, and sirolimus ( 1 - 4 ). (aai.org)
Abnormal5
  • It involves the abnormal development and function of bone marrow cells that produce blood cells and leads to the formation of scar tissue in the bone marrow. (radiationoncologyassociates.co)
  • Bone marrow examination typically reveals an increase in abnormal megakaryocytes (platelet-forming cells) and other abnormalities that are characteristic of myelofibrosis. (radiationoncologyassociates.co)
  • There are multiple mechanisms and differential diagnosis includes: artifactual thrombocytopenia, accelerated platelet destruction (intra- or extra-corpuscular anomalies), deficient production (bone marrow failure, disordered proliferation or thrombopoietin deficiency), and abnormal distribution (disorders associated with splenomegaly or dilution in massive transfusions) ( 1 ). (spandidos-publications.com)
  • This may lead to abnormal growth and causes cells to duplicate. (tecentriq.com)
  • This abnormal growth of melanoma cells can cause the melanoma to spread to other parts of the skin or body. (tecentriq.com)
AGVHD2
  • The purpose of this study is to compare the effectiveness and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids. (mayo.edu)
  • Data from this study indicate that OX40L-OX40 interactions play a central role in the pathogenesis of aGVHD induced by human T cells. (aai.org)
Intravenous3
  • The most frequent causes of secondary ITP were excluded, including lymphoma relapse, and intravenous corticosteroids were started. (spandidos-publications.com)
  • Shortly thereafter, it was demonstrated that intravenous injection of BM cells also provided radioprotection of lethally irradiated mice. (longdom.org)
  • In the case of low-risk HPS, corticosteroids and/or intravenous immunoglobulin or cyclosporine A may be sufficient to control the biological process, but etoposide is recommended as a means of reversing infection-dependent lymphohistiocytic dysregulation in high-risk cases. (biomedcentral.com)
Mesenchymal2
  • In the animal studies, the disease activity index dramatically decreased in the mesenchymal stem cell (MSC) treatment groups compared to the control group. (biomedcentral.com)
  • Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)
Haematopoietic3
  • The distinct MAS phenotype that arises with hypercytokinaemia can be explained by activation of macrophages that are closely juxtaposed to sinusoids that permit direct phagocytic access to haematopoietic lineage cells. (nature.com)
  • Independent origins of fetal liver haematopoietic stem and progenitor cells. (u-tokyo-hemat.com)
  • CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. (u-tokyo-hemat.com)
Umbilical1
Curative1
  • Treatment is often supportive, but Janus kinase 2 (JAK2) inhibitors, such as ruxolitinib , fedratinib , or pacritnib, may decrease symptoms and stem cell transplantation may be curative. (msdmanuals.com)
Malignant4
  • Also, the term "primary cutaneous CD4 + small/medium T-cell lymphoma" was changed to "primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder" because of its indolent clinical behavior and uncertain malignant potential. (medscape.com)
  • Malignant myelofibrosis (sometimes called acute myelofibrosis), is a rare variant of myelofibrosis characterized by pancytopenia, myeloblastosis, and marrow fibrosis that has a more rapidly progressive downhill course and is generally due to a type of acute leukemia called acute megakaryoblastic leukemia. (msdmanuals.com)
  • B-cell maturation antigen (BCMA) is a protein expressed by normal plasma cells and the malignant plasma cells of multiple myeloma. (survivornet.com)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
Organs3
  • In primary myelofibrosis, nucleated red blood cells (normoblasts) and myelocytes are released into the circulation (leukoerythroblastosis) when there is extramedullary hematopoiesis (ie, non-marrow organs have taken over blood cell production because of the fibrosed marrow). (msdmanuals.com)
  • Mechanistically, blocking OX40L-OX40 interaction with an anti-hOX40L reduces infiltration of human T cells in target organs, including liver, gut, lung, and skin. (aai.org)
  • A series of sublethal doses of radiation is directed at the patient's lymphoid tissue (spleen, thymus, and lymph nodes in the neck, chest, and abdomen), with bone marrow and other vital organs shielded from the exposure [ 387 ]. (nanomedicine.com)
Platelets2
Cord blood1
Malignancy-associated1
  • T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated antigens. (survivornet.com)
Proliferation5
  • MicroRNA-155 regulates the proliferation and growth of Waldenström macroglobulinemia cells in vitro and in vivo, by inhibiting MAPK/ERK, PI3/AKT, and NF-κB pathways. (wikipedia.org)
  • Epstein-Barr virus (EBV) infection has been prominently associated with HPS, with clonal proliferation and the hyperactivation of EBV-infected T cells. (biomedcentral.com)
  • Hemophagocytic syndrome (HPS) is a potentially fatal condition due to dysregulated lymphocyte activation and proliferation, mainly characterised by impaired or inactive natural killer (NK) cells and cytotoxic T cells, which leads to macrophage hyperactivation and over-expression of cytokines [ 1 ]. (biomedcentral.com)
  • Overview of Plasma Cell Disorders Plasma cell disorders are a diverse group of disorders of unknown etiology characterized by Disproportionate proliferation of a single clone of B cells Presence of a structurally and electrophoretically. (merckmanuals.com)
  • Initial control of EBV in healthy persons involves NK cells that can kill virus-infected cells ( 3 , 4 ) and secrete IFN-γ, which inhibits B cell proliferation, and monocytes, which release chemokines in response to virus infection ( 5 ). (frontiersin.org)
Recipients2
  • In preparation for receipt of the stem cells, recipients undergo myeloablation to eliminate their own myeloid cells. (medscape.com)
  • The report also includes clinical guidance for adults who have received 7-valent PCV (PCV7) only and adults who are hematopoietic stem cell transplant recipients. (cdc.gov)
Chronic1
  • Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, and anemia with nucleated and teardrop-shaped red blood cells. (msdmanuals.com)
Lymphoma19
Patient's2
  • T cells are taken from a patient's or donor's blood. (survivornet.com)
  • Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. (survivornet.com)
Aspiration3
  • In this setting, immediately perform a bone marrow aspiration and obtain a biopsy from the posterior iliac crest. (medscape.com)
  • Bone marrow aspiration is carried out by a puncture on the level of the sternum or the posterior iliac peaks under local anesthesia by the doctor. (longdom.org)
  • Samples collected from fine-needle aspiration, brushing, cell pellet from pleural effusion, bone metastases without a soft tissue component, and lavage are not acceptable. (bcan.org)
Autoimmune1
  • In recent years, developments in stem cell (SC) biology and regenerative medicine have revealed that SCs unexpectedly can be used to treat autoimmune diseases. (biomedcentral.com)
Complications1
19991
  • Since 1999, various genetic loci related to the activity of perforin and granzyme granules have been associated with genetic autosomal recessive HPS, thus explaining the impaired or absent function of NK cells and cytotoxic T cells [ 2 , 6 ]. (biomedcentral.com)
Liver2
  • When the bone marrow becomes scarred it can't make enough blood cells and this can cause anemia, enlargement of the spleen and liver, fatigue, and other problems. (radiationoncologyassociates.co)
  • Recognizing MAS variants and the important anatomical considerations around macrophage perivascular topography in the marrow, liver and spleen allows for a novel evaluation of other states associated with hypercytokinaemia. (nature.com)
Cancer9
  • Waldenström macroglobulinemia (/ˈvældənstrɒm ˌmækroʊˌɡlɒbjəlɪˈniːmiə/ VAL-dən-strom MAK-roh-GLOB-yə-lin-EE-mee-ə, US also /ˈvɑːldənstrɛm -/ VAHL-dən-strem -⁠) is a type of cancer affecting two types of B cells: lymphoplasmacytoid cells and plasma cells. (wikipedia.org)
  • Notably, we are presenting the first survival data for neoadjuvant Libtayo therapy in cutaneous squamous cell carcinoma and the first results for Libtayo in combination with ubamatamab, our investigational MUC16xCD3 bispecific antibody, in recurrent ovarian cancer. (biospace.com)
  • Ubamatamab is a CD3-targeting bispecific designed to bridge MUC16 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation. (biospace.com)
  • Additional ASCO presentations will share updated clinical results for Libtayo as monotherapy for advanced stages of cutaneous squamous cell carcinoma and non-small cell lung cancer, and in advanced HPV16-positive oropharyngeal cancer. (thepilotnews.com)
  • CAR T-cell therapy is a type of treatment in which a patient or donor's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. (survivornet.com)
  • Multiple myeloma is a cancer of the blood plasma cells. (survivornet.com)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
  • In some cancer types, when cancer cells have high amounts of a protein called PD-L1, they can trick the immune system and avoid being attacked as harmful substances. (bavencio.com)
  • Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
Blood11
Lymphoid1
  • The fungal metabolite cyclosporin A (cyclosporine) [ 384 , 385 ] has a greater specificity for lymphoid T cells than other cells. (nanomedicine.com)
Survival2
  • Inhibition of Src arrests the cell cycle at phase G1 and has little effect on the survival of Waldenström macroglobulinemia or normal cells. (wikipedia.org)
  • I. Assess activity in the form of CAR T cell expansion and persistence, to assess impact on hematopoiesis, 6-month progression free survival (PFS 6mo) rate, duration of response, and 1-year overall survival (OS) rate. (survivornet.com)
Treatment4
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. (survivornet.com)
  • Successful use of allogeneic stem cell transplantation for treatment-refractory mycosis fungoides]. (medscape.com)
  • The only proven effective treatment for the disease is hematopoietic stem cell transplantation. (frontiersin.org)
Clonal1
  • A large clonal or oligoclonal expansion of CD8 cells is observed during infectious mononucleosis ( 6 ). (frontiersin.org)
Abnormalities1
Donors3
Peripheral T-cell and NK-cell1
  • Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. (medscape.com)
Clinical1
  • In clinical trials, stem cell transplantation reduced the CD activity index (SMD − 2.10, P = 0.000), the CD endoscopic index of severity (SMD − 3.40, P = 0.000) and simplified endoscopy score for CD (SMD − 1.71, P = 0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, P = 0.305) compared to control values. (biomedcentral.com)
Immune4
  • It uses a person s own T cells, which are part of the immune system. (survivornet.com)
  • Genetic HPS is heterogeneous and arises from defects in the critical regulatory pathways responsible for the natural termination of immune responses that lead to the failure of the homeostatic removal of cells that are superfluous or dangerous to the host. (biomedcentral.com)
  • Conversely, at the other boundary, immune hypersensitivity with gain of immune function in MHC class II-associated sJIA-AOSD and with chimeric antigen receptor (CAR) T cell therapy also triggers MAS. (nature.com)
  • Both the innate immune response (especially NK cells) and the acquired immune response (virus-specific CD4 and CD8 cells) have a critical role in clearing the infection ( 2 ). (frontiersin.org)
Biopsy1
  • Diagnosis requires bone marrow aspirate and biopsy and exclusion of other conditions that can cause myelofibrosis (secondary myelofibrosis). (msdmanuals.com)
Therapy3
Occurs4
  • In some melanoma cells, a specific error, or mutation, occurs in the BRAF gene (known as BRAF V600). (tecentriq.com)
  • Bone marrow failure eventually occurs, with consequent anemia and thrombocytopenia. (msdmanuals.com)
  • Besides the secretion of pro-inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6), the increased expression of receptor repertoire (pattern recognition receptors, PRR) on APCs, mostly macrophages and dendritic cells, occurs as a result of the release of endogenous and exogenous antigens (damage-associated molecular patterns, DAMPs, and pathogen-associated molecular patterns, PAMPs). (hindawi.com)
  • If mild (Grade 1) rash occurs, consider topical corticosteroids. (nih.gov)
Multiple myeloma3